However, the frequency of CSF CD8+CD20+ T cells was much higher than CSF CD4+ CD20+ T cells both in symptomatic controls (19% vs. 4.9%; p=0.002) and patients with early MS (22% vs. 4.7%; p<0.0001), Figure 2D. The gene discussed is CD8A; the disease is myeloid sarcoma.